News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
LIR Life Sciences Files Provisional Patent Application for Needle-Free Delivery of GLP/GIP-Based Obesity Therapies
LIR Life Sciences files provisional patent for needle-free delivery platform for GLP/GIP therapies in obesity and metabolic diseases, aiming to improve treatment accessibility and adherence -
-
-
COMMUNIQUÉ DE PRESSE
Lir Life Sciences Completes Design of a Comparative Animal Study Investigating Cell-Penetrating Peptide-Mediated Delivery of GLP/GIP-Based Obesity Therapies
Lir Life Sciences Corp. announces a new comparative cell-penetrating peptide-based uptake study for GLP/GIP-based obesity therapies, enhancing transdermal delivery options. The study aims to improve treatment adherence and effectiveness for metabolic conditions -